Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health, Inc. reports developments tied to its medical technology portfolio, commercial agreements and capital structure. The company focuses on life-saving and life-enhancing medical solutions through acquired or developed assets, intellectual property and technologies. Recent company updates include exclusive worldwide marketing and distribution rights for BreastCheck™ through Odyssey Medical Devices, development work on the patented Save A Life choking rescue device, and commercial service arrangements intended to add recurring revenue.
Odyssey Health news also includes financing facilities, promissory-note activity, operating and financial results, shareholder voting matters, and completed portfolio transactions such as the sale of its neurological drug-therapy assets related to concussion, Niemann Pick Disease Type C, powder formulation technology and a nasal delivery device.
Odyssey Health, Inc. (OTC Pink: ODYY) announced favorable safety results from Cohort II of its Phase I clinical trial for PRV-002, a novel drug to treat concussions. Conducted at Nucleus Network, this cohort included six healthy volunteers with no severe adverse events. All vital signs and blood tests remained normal, leading to unanimous approval for the next cohort with increased dosage. CEO Michael Redmond highlighted ongoing discussions for Phase II/III trials. The global concussion treatment market is projected to grow from $6.9 billion in 2020 to $8.9 billion by 2027.
Odyssey Health, Inc. (OTC Pink: ODYY) will be featured in a C-Level interview on The RedChip Money Report®, airing June 11 at 7 p.m. ET on Bloomberg TV, reaching 73 million homes in the U.S. CEO Michael Redmond discusses Odyssey's innovative concussion treatment and other medical solutions, targeting a $400 billion market. The company focuses on unmet medical needs with products like CardioMap® and Save-A-Life®, aiming to set industry standards. The interview promises insights on human trials and strategic objectives.
Odyssey Health, Inc. (OTC Pink: ODYY) announced positive safety results from Cohort I of their Phase I clinical trial for PRV-002, a novel drug aimed at treating concussions. Conducted at Nucleus Network, the trial involved eight healthy subjects who reported no severe adverse effects, indicating that PRV-002 was well-tolerated. Vital signs and lab results remained normal. With a global concussion treatment market valued at $6.9 billion in 2020, Odyssey is optimistic about the drug's potential efficacy in future trials, as stated by executives.
Odyssey Health, Inc. (OTC Pink: ODYY) announced positive outcomes from the initial group of patients in their Phase I clinical trial for PRV-002, a novel treatment for concussions. The drug has been shown to be safe and well-tolerated in five healthy subjects, with no serious adverse events reported. Every year, over three million concussions occur in the U.S., presenting a significant unmet medical need. The company aims to complete the trial and present findings to the FDA, with plans for a subsequent Phase II trial focused on military applications.
Odyssey Health, Inc. (OTC Pink: ODYY) has appointed Vice Admiral (r) Timothy Szymanski to its Military Advisory Board. Szymanski, a veteran with over 36 years of service, aims to enhance the company's efforts in developing PRV-002, a drug designed to treat concussions. Currently in Phase 1 clinical trials, PRV-002 shows promise in neuroprotection, potentially addressing the urgent needs of millions affected by concussions annually. Odyssey focuses on life-saving medical solutions, emphasizing strategies that improve service members' well-being.
Odyssey Group International (OTC Pink: ODYY) has established a Military Advisory Board to enhance its focus on treating traumatic brain injuries (TBI) with its drug candidate, PRV-002, currently in Phase 1 clinical trials. The board includes notable military leaders such as Major General Jim Linder and Commanding General Francis Beaudette, who bring extensive experience in addressing TBIs, especially in the military context. Odyssey aims to develop an intranasal device to deliver PRV-002 for immediate treatment post-concussion, addressing a significant medical need.
Odyssey Health, Inc. (OTC Pink: ODYY) is advancing its clinical trial of PRV-002, a novel neurosteroid aimed at treating concussions. Conducted by Nucleus Network in Melbourne, the trial is significant as it seeks to address a critical gap in concussion treatment. NFL Hall of Famer Brett Favre is involved as a sports advisory board member, although he is not a participant in the trial. The medication, delivered nasally, aims to reduce brain swelling and improve recovery outcomes, with a target population that includes sports players and others at risk of brain injuries.
Odyssey Group International, Inc. (OTC Pink: ODYY) announced a $500,000 donation from Erase PTSD Now and the Glenn Greenberg and Linda Vester Foundation to support Phase 1 human clinical trials of PRV-002, a drug aimed at treating concussion. CEO Michael Redmond emphasized the significance of this funding in progressing the trials. The partnership aims to collect data on PTSD and concussion links to enhance treatment for military veterans. PRV-002 is designed to alleviate concussion symptoms and reduce brain inflammation, with the goal of improving recovery outcomes for soldiers.
Odyssey Group International, Inc. (OTC: ODYY) has filed a provisional patent for a novel nasal drug delivery device intended for treating concussions. This device uses a dual wall dispensing system to enhance drug deposition directly into the nasal cavity and olfactory region, aiming to improve treatment outcomes for traumatic brain injuries. CEO Michael Redmond emphasized the device’s potential to deliver PRV-002, a neuroprotective synthetic neurosteroid, rapidly to the brain while minimizing side effects. The company targets further development of neurological drugs utilizing this technology.
Odyssey Group International (OTC: ODYY) announced the successful initiation of its Phase 1 clinical trial for PRV-002, a nasal neurosteroid aimed at treating concussion. Enrollment and screening of subjects have commenced, with the first cohort scheduled for dosing shortly. The trial will evaluate pharmacokinetics and tolerability across three dosage levels. The unique delivery method and the pressing need for concussion treatments are expected to facilitate participant enrollment and compliance. This update indicates significant progress in Odyssey's drug development pipeline.